Top

Current Fungal Infection Reports

Published in:

01-03-2018 | Pharmacology and Pharmacodynamics of Antifungal Agents

Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy

Authors: C. Roger, M. Sasso, J. Y. Lefrant, L. Muller

Published in: Current Fungal Infection Reports | Issue 1/2018

Abstract

Purpose of Review

The incidence of systemic fungal infections is increasing among patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in one third of ICU patients and approximately 5% require renal replacement therapy (RRT). Among those requiring RRT, continuous RRT (CRRT) is used in more than 70% of cases. This review aims to summarize antifungal dosing management in ICU patients receiving CRRT.

Recent Findings

For most antifungal agents, including new azoles such as posaconazole and isavuconazole, CRRT does not significantly affect antifungal pharmacokinetics (PK) mainly due to drug liver elimination and high protein binding. For fluconazole, increased dose is recommended during CRRT taking into account the type of CRRT mode (CVVHF or CVVHDF), membrane surface, and effluent and dialysis flow rates. A dose increase for itraconazole seems also necessary during CRRT; a dose decrease for flucytosine is probably necessary but data are too scarce to give a strong recommendation.

Summary

In ICU patients receiving CRRT, no dosing adjustment is required for the majority of antifungal agents commonly used to treat invasive fungal infections (IFIs) excepted for fluconazole, itraconazole, and flucytosine. Due to high PK variability, therapeutic drug monitoring should be considered in ICU patients receiving CRRT.

Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40(6):839–45. https://doi.org/10.1007/s00134-014-3310-z.CrossRefPubMed

Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho F, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38(12):1930–45. https://doi.org/10.1007/s00134-012-2695-9.CrossRefPubMed

Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41(9):1601–10. https://doi.org/10.1007/s00134-015-3866-2.CrossRefPubMed

Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58(8):1072–83. https://doi.org/10.1093/cid/ciu027.CrossRefPubMed

Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, et al. Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients study. Crit Care. 2015;19(1):33. https://doi.org/10.1186/s13054-015-0758-3.CrossRefPubMedPubMedCentral

Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8. https://doi.org/10.1001/jama.294.7.813. CrossRefPubMed

Friedrich JO, Wald R, Bagshaw SM, Burns KE, Adhikari NK. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. Crit Care. 2012;16(4):R146. https://doi.org/10.1186/cc11458.CrossRefPubMedPubMedCentral

Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46(12):997–1038. https://doi.org/10.2165/00003088-200746120-00003.CrossRefPubMed

Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37(7):2268–82. https://doi.org/10.1097/CCM.0b013e3181aab3d0.CrossRefPubMed

10.

Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15(3):R137. https://doi.org/10.1186/cc10257.CrossRefPubMedPubMedCentral

11.

Prasad R, Banerjee A, Shah AH. Resistance to antifungal therapies. Essays Biochem. 2017;61(1):157–66. https://doi.org/10.1042/EBC20160067.CrossRefPubMed

12.

Sanglard D, Coste A, Ferrari S. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 2009;9(7):1029–50. https://doi.org/10.1111/j.1567-1364.2009.00578.x.CrossRefPubMed

13.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. https://doi.org/10.1093/cid/civ933. CrossRefPubMed

14.

Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med. 2014;40(9):1303–12. https://doi.org/10.1007/s00134-014-3408-3.CrossRefPubMedPubMedCentral

15.

Lortholary O, Renaudat C, Sitbon K, Desnos-Ollivier M, Bretagne S, Dromer F, et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med. 2017;43(5):652–62. https://doi.org/10.1007/s00134-017-4743-y.CrossRefPubMedPubMedCentral

16.

Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother. 1997;40(5):695–700. https://doi.org/10.1093/jac/40.5.695.CrossRefPubMed

17.

Pittrow L, Penk A. Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses. 1999;42(Suppl 2):87–90. https://doi.org/10.1111/j.1439-0507.1999.tb00020.x.CrossRef

18.

Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol. 2000;56(9–10):671–8. https://doi.org/10.1007/s002280000216.CrossRefPubMed

19.

Yagasaki K, Gando S, Matsuda N, Kameue T, Ishitani T, Hirano T, et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med. 2003;29(10):1844–8. https://doi.org/10.1007/s00134-003-1980-z.CrossRefPubMed

20.

Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol Dial Transplant. 2006;21(4):1019–23. https://doi.org/10.1093/ndt/gfi284.CrossRefPubMed

21.

Prowle JR, Schneider A, Bellomo R. Clinical review: optimal dose of continuous renal replacement therapy in acute kidney injury. Crit Care. 2011;15(2):207. https://doi.org/10.1186/cc9415.CrossRefPubMedPubMedCentral

22.

Lopez ND, Phillips KM. Fluconazole pharmacokinetics in a morbidly obese, critically ill patient receiving continuous venovenous hemofiltration. Pharmacotherapy. 2014;34(9):e162–8. https://doi.org/10.1002/phar.1470.CrossRefPubMed

23.

Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006;45(7):649–63. https://doi.org/10.2165/00003088-200645070-00002.CrossRefPubMed

24.

Robatel C, Rusca M, Padoin C, Marchetti O, Liaudet L, Buclin T. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. J Antimicrob Chemother. 2004;54(1):269–70. https://doi.org/10.1093/jac/dkh310.CrossRefPubMed

25.

Fuhrmann V, Schenk P, Jaeger W, Miksits M, Kneidinger N, Warszawska J, et al. Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2007;60(5):1085–90. https://doi.org/10.1093/jac/dkm349.CrossRefPubMed

26.

Radej J, Krouzecky A, Stehlik P, Sykora R, Chvojka J, Karvunidis T, et al. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2011;33(4):393–7. https://doi.org/10.1097/FTD.0b013e3182205d93.CrossRefPubMed

27.

Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, et al. Evaluation of sulfobutylether-beta-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015;19(1):32. https://doi.org/10.1186/s13054-015-0753-8.CrossRefPubMedPubMedCentral

28.

Luke DR, Tomaszewski K, Damle B, Schlamm HT. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291–301. https://doi.org/10.1002/jps.22109.CrossRefPubMed

29.

Lilly CM, Welch VL, Mayer T, Ranauro P, Meisner J, Luke DR. Evaluation of intravenous voriconazole in patients with compromised renal function. BMC Infect Dis. 2013;13(1):14. https://doi.org/10.1186/1471-2334-13-14.CrossRefPubMedPubMedCentral

30.

Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32(Suppl 1):67–87. https://doi.org/10.1111/j.1439-0507.1989.tb02296.x.CrossRefPubMed

31.

Coronel B, Persat F, Dorez D, Moskovtchenko JF, Peins MA, Mercatello A. Itraconazole concentrations during continuous haemodiafiltration. J Antimicrob Chemother. 1994;34(3):448–9. https://doi.org/10.1093/jac/34.3.448.CrossRefPubMed

32.

Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46(5):1581–2. https://doi.org/10.1128/AAC.46.5.1581-1582.2002.CrossRefPubMedPubMedCentral

33.

Lipp HP. Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol. 2010;70(4):471–80. https://doi.org/10.1111/j.1365-2125.2010.03680.x. CrossRefPubMedPubMedCentral

34.

Li X, Brown N, Chau AS, Lopez-Ribot JL, Ruesga MT, Quindos G, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother. 2004;53(1):74–80. https://doi.org/10.1093/jac/dkh027. CrossRefPubMed

35.

Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737–79. https://doi.org/10.1007/s15010-017-1042-z.CrossRefPubMedPubMedCentral

36.

Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit. 2011;33(4):387–92. https://doi.org/10.1097/FTD.0b013e31821fb197.CrossRefPubMed

37.

Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–95. https://doi.org/10.1128/AAC.47.9.2788-2795.2003.CrossRefPubMedPubMedCentral

38.

Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol. 2005;45(2):185–92. https://doi.org/10.1177/0091270004271402.CrossRefPubMed

39.

Morris AA, Mueller SW, Rower JE, Washburn T, Kiser TH. Evaluation of sulfobutylether-beta-cyclodextrin exposure in a critically ill patient receiving intravenous posaconazole while undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2015;59(10):6653–6. https://doi.org/10.1128/AAC.01493-15.CrossRefPubMedPubMedCentral

40.

Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9. https://doi.org/10.1016/S0140-6736(15)01159-9.CrossRefPubMed

41.

Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300. https://doi.org/10.2147/IDR.S102207.CrossRefPubMedPubMedCentral

42.

European Medicines Agency (2015) Cresemba isavuconazole. Available at: http://wwwemaeuropaeu/ema/indexjsp?curl=pages/medicines/human/medicines/002734/human_med_001907jsp&mid=WC0b01ac058001d124; visited 15 October 2017.

43.

Townsend RW, Akhtar S, Alcorn H, Berg JK, Kowalski DL, Mujais S, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73(6):669–78. https://doi.org/10.1007/s00228-017-2213-7.CrossRefPubMedPubMedCentral

44.

Kovanda LL, Desai AV, Lu Q, Townsend RW, Akhtar S, Bonate P, et al. Isavuconazole population pharmacokinetic analysis using nonparametric estimation in patients with invasive fungal disease (results from the VITAL study). Antimicrob Agents Chemother. 2016;60(8):4568–76. https://doi.org/10.1128/AAC.00514-16.CrossRefPubMedPubMedCentral

45.

Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37. https://doi.org/10.1111/1469-0691.12039.CrossRefPubMed

46.

Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006;50(8):2719–27. https://doi.org/10.1128/AAC.00111-06.CrossRefPubMedPubMedCentral

47.

EMA. European Medicines Agency Cancidas: EPAR http://www.emaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000379/WC500021033pdf Last updated 1st June 2015.

48.

Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother. 2002;46(3):739–45. https://doi.org/10.1128/AAC.46.3.739-745.2002.CrossRefPubMedPubMedCentral

49.

Weiler S, Seger C, Pfisterer H, Stienecke E, Stippler F, Welte R, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2013;57(8):4053–7. https://doi.org/10.1128/AAC.00335-13.CrossRefPubMedPubMedCentral

50.

Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Bruggemann RJ, et al. Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration. Clin Pharmacokinet. 2016;56(9):1057–68. https://doi.org/10.1007/s40262-016-0495-z.CrossRef

51.

Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol. 2011;51(2):202–11. https://doi.org/10.1177/0091270010374853.CrossRefPubMed

52.

Wurthwein G, Cornely OA, Trame MN, Vehreschild JJ, Vehreschild MJ, Farowski F, et al. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother. 2013;57(4):1664–71. https://doi.org/10.1128/AAC.01912-12.CrossRefPubMedPubMedCentral

53.

European Medicines Agency. 2014. Summary of product characteristics. EMA, London, United Kingdom. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000734/WC500031075.pdf.

54.

Pasipanodya JP, Hall RG 2nd, Gumbo T. In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. Clin Pharmacol Ther. 2015;97(3):292–7. https://doi.org/10.1002/cpt.38.CrossRefPubMed

55.

Zomp A, Bookstaver PB, Ahmed Y, Turner JE, King C. Micafungin therapy in a critically ill, morbidly obese patient. J Antimicrob Chemother. 2011;66(11):2678–80. https://doi.org/10.1093/jac/dkr323.CrossRefPubMed

56.

Vossen MG, Knafl D, Haidinger M, Lemmerer R, Unger M, Pferschy S, et al. Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients. Antimicrob Agents Chemother. 2017;61(8):e02425–16. https://doi.org/10.1128/AAC.02425-16.CrossRefPubMedPubMedCentral

57.

Maseda E, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofino A, Roberts JA, et al. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. J Antimicrob Chemother. 2014;69(6):1624–32. https://doi.org/10.1093/jac/dku013.CrossRefPubMed

58.

Kishino S, Ohno K, Shimamura T, Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transpl. 2004;18(6):676–80. https://doi.org/10.1111/j.1399-0012.2004.00272.x.CrossRef

59.

Martial LC, Ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, et al. Population pharmacokinetic model and pharmacokinetic target attainment of micafungin in intensive care unit patients. Clin Pharmacokinet. 2017;56(10):1197–206. https://doi.org/10.1007/s40262-017-0509-5.CrossRefPubMedPubMedCentral

60.

Jullien V, Azoulay E, Schwebel C, Le Saux T, Charles PE, Cornet M, et al. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother. 2017;72(1):181–9. https://doi.org/10.1093/jac/dkw352.CrossRefPubMed

61.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–93. https://doi.org/10.1086/520980.CrossRefPubMed

62.

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000788/WC500020673.pdf. Visited 17 October 2017.

63.

Leitner JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Jager W, et al. Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration. J Antimicrob Chemother. 2011;66(4):880–4. https://doi.org/10.1093/jac/dkq545.CrossRefPubMed

64.

Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother. 2009;53(12):5102–7. https://doi.org/10.1128/AAC.01042-09.CrossRefPubMedPubMedCentral

65.

Aguilar G, Azanza JR, Carbonell JA, Ferrando C, Badenes R, Parra MA, et al. Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2014;69(6):1620–3. https://doi.org/10.1093/jac/dkt542.CrossRefPubMed

66.

Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res. 2000;17(12):1494–502. https://doi.org/10.1023/A:1007605024942.CrossRefPubMed

67.

Gallis HA, Drew RH, Pickard WW, Amphotericin B. 30 years of clinical experience. Rev Infect Dis. 1990;12(2):308–29. https://doi.org/10.1093/clinids/12.2.308.CrossRefPubMed

68.

Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002;46(3):828–33. https://doi.org/10.1128/AAC.46.3.828-833.2002.CrossRefPubMedPubMedCentral

69.

http://www.gilead.com/-/media/files/pdfs/medicines/other/ambisome/ambisome_pi.pdf.

70.

Bellmann R, Egger P, Djanani A, Wiedermann CJ. Pharmacokinetics of amphotericin B lipid complex in critically ill patients on continuous veno-venous haemofiltration. Int J Antimicrob Agents. 2004;23(1):80–3. https://doi.org/10.1016/j.ijantimicag.2003.05.014.CrossRefPubMed

71.

Bellmann R, Egger P, Gritsch W, Bellmann-Weiler R, Joannidis M, Kaneider N, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother. 2003;51(3):671–81. https://doi.org/10.1093/jac/dkg139.CrossRefPubMed

72.

Tomlin M, Priestley GS. Elimination of liposomal amphotericin by hemodiafiltration. Intensive Care Med. 1995;21(8):699–700. https://doi.org/10.1007/BF01711556.CrossRefPubMed

73.

Alvarez-Lerma F, Rodriguez M, Soriano MC, Catalan M, Llorente AM, Vidart N, et al. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy. Rev Esp Quimioter. 2013;26(4):360–8.PubMed

74.

Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–9. https://doi.org/10.1093/jac/46.2.171.CrossRefPubMed

75.

Tassel D, Madoff MA. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA. 1968;206(4):830–2. https://doi.org/10.1001/jama.1968.03150040042009.CrossRefPubMed

76.

Schonebeck J, Polak A, Fernex M, Scholer HJ. Pharmacokinetic studies on the oral antimycotic agent 5-fluorocytosine in individuals with normal and impaired kidney function. Chemotherapy. 1973;18(6):321–36. https://doi.org/10.1159/000221279.CrossRefPubMed

77.

Alcotin (2001) Summary of product characteristics. ICN Pharm Electron Med compendium, July 2001.

78.

Thomson AH, Shankland G, Clareburt C, Binning S. Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration. Intensive Care Med. 2002;28(7):999. https://doi.org/10.1007/s00134-002-1340-4.CrossRefPubMed

79.

Roberts JA, Udy AA, O'Donoghue S, Briscoe S, Paterson DL, Lipman J. Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. Int J Antimicrob Agents. 2009;34(4):383–4. https://doi.org/10.1016/j.ijantimicag.2009.05.005.CrossRefPubMed

80.

Kunka ME, Cady EA, Woo HC, Thompson Bastin ML. Flucytosine pharmacokinetics in a critically ill patient receiving continuous renal replacement therapy. Case Rep Crit Care. 2015;2015(927496):1–5. https://doi.org/10.1155/2015/927496.

Title: Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy
Authors: C. Roger
M. Sasso
J. Y. Lefrant
L. Muller
Publication date: 01-03-2018
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 1/2018
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0305-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts

Pathogenesis and Pathology of Invasive Aspergillosis

A Case for Antifungal Stewardship

Epidemiology of Histoplasmosis

Emergomyces: a New Genus of Dimorphic Fungal Pathogens Causing Disseminated Disease among Immunocompromised Persons Globally

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page